Development of Inflammatory Angiogenesis by Local Stimulation of Fas In Vivo

By Luigi Biancone,* Antonella De Martino,* Viviana Orlandi,§ Pier Giulio Conaldi,§ Antonio Toniolo,§ and Giovanni Camussi*

From the *Chair of Nephrology and 1Chair of Microbiology, Department of Clinical and Biological Sciences, University of Pavia, Varese, Italy

Summary

Fas–Fas ligand interaction is thought to be a crucial mechanism in controlling lymphocyte expansion by inducing lymphocyte apoptosis. However, Fas is also broadly expressed on nonlymphoid cells, where its function in vivo remains to be determined. In this study, we describe the development of inflammatory angiogenesis induced by agonistic anti-Fas mAb Jo2 in a murine model where Matrigel is used as a vehicle for the delivery of mediators. The subcutaneous implants in mice of Matrigel containing mAb Jo2 became rapidly infiltrated by endothelial cells and by scattered monocytes and macrophages. After formation and canalization of new vessels, marked intravascular accumulation and extravasation of neutrophils were observed. Several mast cells were also detected in the inflammatory infiltrate. The phenomenon was dose and time dependent and required the presence of heparin. The dependency on activation of Fas is suggested by the observation that the inflammatory angiogenesis was restricted to the agonistic anti-Fas mAb and it was absent in lpr Fas-mutant mice. Apoptotic cells were not detectable at any time inside the implant or in the surrounding tissue, suggesting that angiogenesis and cell infiltration did not result from recruitment of phagocytes by apoptotic cells but rather by a stimulatory signal through Fas-engagement. These findings suggest a role for Fas–Fas ligand interaction in promoting local angiogenesis and inflammation.

Fas and structurally related glycoproteins form a family of surface receptors that control cell proliferation, survival, or apoptosis (1). On the other side, their ligands are homologue trimers present on soluble and/or cell-associated forms that may act as growth or death factors for several cell types. In particular, Fas ligand (FasL) is expressed on the cell surface and released by T cells (2, 3), monocytes, and neutrophils (4). So far, the biological importance of Fas-FasL interaction has been investigated in T lymphocytes, where it controls clonal deletion of autoreactive lymphocytes and mediates activation-induced suicide of T cells through a death signal transduced by Fas (1). However, several cell types, such as endothelial cells (5), monocytes (4), epithelial cells (6), and certain tumor lineages (7), are resistant to Fas-mediated apoptosis. Other cells, such as neutrophils (4) and B cells (8), rapidly acquire resistance after stimulation with growth factors or cytokines. In addition, genetic deficiency of Fas or FasL does not affect organ development with the exception of the lymphoid compartment. Therefore, the role of Fas-FasL interaction in nonlymphoid cells remains to be elucidated, and it might also involve mechanisms different from apoptosis induction. Indeed, this hypothesis is fueled by an increasing number of observations suggesting that Fas may transduce cell activation signals independently or as an alternative to cell death (9–12).

This study explores the effect of an in situ Fas stimulation by agonistic monoclonal antibodies implanted in vivo within Matrigel. In this model, anti-Fas mAb triggers neoangiogenesis and local infiltration of inflammatory cells, independently from apoptosis.

Materials and Methods

Reagents. Hamster anti-mouse Fas Jo2 was from PharMingen (San Diego, CA) and rat anti-mouse Fas RMF6 was from MBL (Nagoya, Japan). Purified hamster IgGs (Cappel Laboratories Inc., West Chester, PA) were used as control.

Murine Angiogenesis Assay. Wild-type and carrier of the lpr mutation in the Fas gene C57Bl/6 (13) mice were from Jackson Laboratories (Bar Harbor, Maine). Animals were used at 6 wk of age. Angiogenesis was assayed as growth of blood vessels from subcutaneous tissue into a solid gel of basement membrane containing the test sample (14). 6 mice per condition in each experiment were used. As standard procedure, Matrigel (8.13 mg/ml; Becton Dickinson Labware, Bedford, MA) in liquid form at 4°C, was mixed with heparin (64 U/ml, Sigma Chem. Co., St. Louis, MO) and the experimental substances and injected (0.25 ml) into the abdominal subcutaneous tissue of mice, along the peritoneal midline. At various times, mice were killed and gels were processed for light microscopy, detection of nonspecific esterase activity, and immunohistochemistry as previously described (15). Rabbit anti-vWF (Sigma), anti-VEGF, anti-flk-1 and anti-b-FGF on July 22, 2018 jem.rupress.org Downloaded from http://doi.org/10.1084/jem.186.1.147 Published Online: 7 July, 1997 | Supp Info:
(Santa Cruz Biotechnology, Santa Cruz, CA), and anti-L3/T4 and Ly2 monoclonal antibodies (Cedarlane, Ontario, Canada), as well as control rabbit and mice IgG, were used as primary antibodies for indirect immunofluorescence. FITC-conjugated anti-rabbit IgG and anti-rat IgG were used as secondary antibodies (Cappel Laboratories). Direct immunofluorescence staining was performed with anti-MAC-1 FITC-conjugated monoclonal antibodies (Cedarlane). Mast cells were stained metachromatically with 1% Toluidine blue, pH 3.5, for 30 min. Apoptotic cells were detected in situ through the staining of DNA fragments with the TUNEL assay (Apotag Oncor, Gaithersburg, MD) (16). Tissue from rat regressing mammary glands obtained at the fourth day after weaning was used as positive control for the technique.

Vessel area and the total Matrigel area were planimetrically as-
Results

Subcutaneous injection in mice of Matrigel containing the agonistic anti-Fas mAb Jo2 caused rapid neovascularization and infiltration of inflammatory cells within the implant (Fig. 1). The phenomenon is dose and time-dependent (Figs. 2 and 3). The minimal effective dose was 100 ng/ml. Initial infiltration of cells was observed as early as 24 h after injection (Fig. 2 A) and the infiltrating cells were mainly endothelial cells (Fig. 1 A), as detected by immunofluorescence staining for vWF (Fig. 4, A and B) and MAC-1+ (Fig. 4 C) and aspecific esterase plus monocytes. Polymorphonuclear neutrophils (PMN) were seen initially at the periphery of Matrigel implant, then within the lumen of neoformed capillary sprouts (Fig. 1 D) and finally around the neoformed vessels (Fig. 1 F). Only scattered lymphocytes CD4+ or CD8+ were detected. Several mast cells (Fig. 1 F), metachromatically stained by Toluidine blue, were also detected within the Matrigel and the inflammatory infiltrate surrounding the neoformed vessels. Maximal angiogenesis was observed at day 6 with formation of canalized vessels (Fig. 1 G and 3 A). At that time, ~50% of neoformed vessels were surrounded by an intense infiltration of inflammatory cells similar to granulation-like tissue (Fig. 1 E). Control purified hamster IgG and a non-signaling anti–mouse Fas mAb RMF6 (17) were completely ineffective (Fig. 5). mAb Jo2 was endotoxin free as tested by Limulus assay and in selected experiments prein-

Figure 2. Quantitative and qualitative evaluation of cells infiltrating Matrigel. (A) Time course studies on infiltration induced by 5 μg/ml anti-Fas mAb Jo2 or control hamster IgG. Endothelial cells (EC) were counted as vWF-positive cells; monocytes (Mo) were counted as MAC-1-esterase-positive cells; and PMN were counted in section stained by hematoxylin and eosin. (B) Dose-dependent studies on Matrigel infiltration observed 6 d after stimulation with anti-Fas mAb Jo2 or control hamster IgG. The results were expressed as a mean ± SE of cell/field (×400). ANOVA with Dunnett multi-comparison test was performed: control hamster IgG vs anti-Fas mAb Jo2: (A) EC * P < 0.05; Mo • P < 0.05; PMN § P < 0.05. (B) total cell count *P < 0.05.

Figure 3. Quantitative evaluation of neoformed vessels infiltrating Matrigel. (A) Time course studies on neoangiogenesis induced by 5 μg/ml anti-Fas mAb Jo2 or control hamster IgG. (B) Dose-dependent studies on neoangiogenesis observed 6 d after implantation of Matrigel containing anti-Fas mAb Jo2 or control hamster IgG. The results were expressed as percentage ± SE of the vessel area to the total Matrigel area. ANOVA with Dunnett multi-comparison test was performed between control hamster IgG and anti-Fas mAb Jo2 (*P < 0.05).
cubation for 30 min of the antibody with 5 μg/ml polymyxin B, which complexes and inactivates endotoxin, did not abrogate the inflammatory angiogenesis induced by this mAb (data not shown). All the animals that were implanted with Matrigel containing mAb Jo2 remained apparently healthy and active and the histological examination of the liver did not show macroscopic alterations.

The requirement of heparin for the development of Fas-induced angiogenesis suggests the involvement of heparin-binding angiogenic factors (Fig. 5). By immunohistochemistry, VEGF and Flk-1 (Fig. 4, D and E), but not b-FGF (Fig. 4 F), were detectable on the endothelial cells infiltrating M atrigel and lining the neoformed capillaries, suggesting that VEGF rather than b-FGF may have an autocrine role in Fas-induced neovascular formation.

To explore the relevance of Fas-stimulation in the angiogenesis induced by mAb Jo2, experiments were performed in lpr mice. mAb Jo2 did not elicit neangiogenesis or inflammatory infiltration of M atrigel in lpr mice (Fig. 5). In contrast, b-FGF-induced angiogenesis was normally maintained in these mutants.

In situ detection of apoptotic cells by the TUNEL technique indicated the absence of significant apoptosis in the cells infiltrating M atrigel and in the surrounding tissue at any time tested (6 h, 12 h, 24 h, 4 d, and 6 d after injection) (Fig. 1 H). Tissue from rat regressing mammary glands obtained at the fourth day after weaning and used as positive control, displayed apoptotic cells along the acini (Fig. 1 I).

Incubation of this tissue without TdT enzyme, as negative control, resulted in absence of staining.

Discussion

Interaction of Fas with its ligand, FasL, or agonistic anti-Fas mAbs and role of heparin in Fas-induced angiogenesis. 5 μg/ml anti-Fas mAb Jo2 or RMF6 were used. As standard procedure M atrigel was supplemented with 64 U/ml heparin (see Materials and Methods). In selected experiments heparin was omitted or 64 μg/ml protamine was added. b-FGF was used at the dose of 10 ng/ml. The results were expressed as percentage ± SE of the vessel area to the total M atrigel area. ANOVA with Newman-Keuls multi-comparison test was performed: control vs. mAb Jo2, mAb RMF6, and b-FGF (* < 0.05); mAb Jo2 in wild-type mice vs. mAb RMF6, mAb Jo2 without heparin, mAb Jo2 plus protamine, mAb Jo2 in lpr mice (§ < 0.05).

Figure 5. Angiogenesis in wild-type mice and in mice lpr Fas-mutant stimulated with agonistic (mAb Jo2) and nonagonistic (mAb RMF6) anti-Fas mAbs and role of heparin in Fas-induced angiogenesis. 5 μg/ml anti-Fas mAb Jo2 or RMF6 were used. As standard procedure M atrigel was supplemented with 64 U/ml heparin (see Materials and Methods). In selected experiments heparin was omitted or 64 μg/ml protamine was added. b-FGF was used at the dose of 10 ng/ml. The results were expressed as percentage ± SE of the vessel area to the total M atrigel area. ANOVA with Newman-Keuls multi-comparison test was performed: control vs. mAb Jo2, mAb RMF6, and b-FGF (* < 0.05); mAb Jo2 in wild-type mice vs. mAb RMF6, mAb Jo2 without heparin, mAb Jo2 plus protamine, mAb Jo2 in lpr mice (§ < 0.05).
In mice subcutaneous implants of Matrigel containing anti-Fas mAb are rapidly neovascularized and infiltrated by inflammatory cells. Neangiogenesis is triggered also by VEGF (21), b-FGF (14), TNF-α (15), and PAF (15), however, no inflammatory infiltration is caused by these agents. Therefore, the inflammatory angiogenesis observed in the present study is peculiar of Fas-stimulation. Indeed, a nonsignaling anti-Fas mAb (17) failed in inducing this effect, suggesting that anti-Fas mAb does not act simply by anchoring or facilitating the interaction of Fas-expressing cells with the Matrigel. In addition, the role of a functional activation of Fas is suggested by the absence of inflammatory angiogenesis in Fas-deficient mice stimulated with agonistic anti-Fas mAb.

A time course analysis of apoptosis did not reveal the presence of apoptotic cells in the surrounding tissue or inside the Matrigel containing the anti-Fas mAb, suggesting that inflammatory cell accumulation cannot be ascribed to the recruitment of phagocytes by apoptotic cells. Cell necrosis was not observed.

Interestingly, in a model of xenotransplantation, FasL expression by a graft implanted subcutaneously in nude mice elicited a rejection reaction which was mediated by neutrophil recruitment and activation (22). Our results demonstrate that in the subcutaneous site Fas-stimulation induces per se a marked angiogenic and inflammatory response. The local prevalence of cells naturally resistant to Fas-mediated apoptosis and/or the availability of survival signals, such as growth factor supply and extracellular matrix interaction, may account for the lack of apoptosis in this model. Therefore, it is conceivable that Fas stimulation by agonistic mAb may uncover in this model the cell activation rather than the apoptotic signals. Furthermore, the observation that heparin was required for Fas-induced inflammatory angiogenesis, suggests that heparin-binding growth factors may be involved as secondary mediators. The immunohistochemical study revealed the expression of VEGF and its receptor Flk-1 by the endothelial cells infiltrating Matrigel or lining the neoformed vessels. In the present experimental model, multiple cell types may act as a target for anti-Fas antibodies. However, the early infiltrating cells were endothelial cells and monocytes. The time-course studies showed that the recruitment of PMN follows that of endothelial cells. When the vessels are canaleized PMN were seen adherent to the abluminal surface of endothelial cells and in the extravascular space around the neoformed vessels, suggesting a leukocyte recruitment dependent on endothelial cell activation. Neutrophils constitutively express both Fas and its ligand and in vitro they become resistant to Fas-mediated apoptosis when cultured in the presence of G-CSF, GM-CSF, IFN-γ, TNF-α, or dexamethazone (4). In addition, the deficiency of Fas in lpr mice seems to impair the inflammatory response involving polymorphonuclear leukocytes extravasation in the course of host defense against bacteria (23).

In conclusion, Fas-FasL interaction is likely to occur at the sites of inflammation because FasL may be expressed by several inflammatory cells such as T cells, monocytes and neutrophils (4). Furthermore, FasL may also be released by proteolytic cleavage as a biologically active soluble form (3, 24), which is detectable in several pathologic conditions (24), including synovial fluids of patients with rheumatoid arthritis (Biancone, L., and G. Camussi, unpublished observation). Such a proteolytic process seems to be catalyzed by metalloproteinases that are usually overproduced during inflammation (24).

This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC), Targeted Project Angiogenesis, by MURST 40% and 60%, and by the Istituto Superiore di Sanità, Research Project "Artificial organs and organ transplantation" to G. Camussi.

Address correspondence to Giovanni Camussi, Dip. di Scienze Cliniche e Biologiche, Via L. Borri 57, 21100 Varese, Italy. Phone: 39-332-278311; Fax: 39-332-260017.

Received for publication 27 January 1997 and in revised form 14 April 1997.

References

1. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science (Wash. DC). 267:1449–1456.
2. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169–1178.
3. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO (Eur. Mol. Biol. Organ.) J. 14:1129–1135.
4. Liles, W.C., P.A. Kiener, J.A. Ledbetter, A. Aruffo, and S.J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184:429–440.
5. Richardson, B.C., N.D. Lalwani, K.J. Johnson, and R.M. Marks. 1994. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24:2640–2645.
6. Boonstra, J.C., F.J. van der Woude, J.C. Laterveer, P.C. Weever, L.A. van Es, M.R. Daha, and C. van Kooten. 1996. Fas (CD95) is expressed on tubular epithelial cells in situ and in vitro, but Fas-mediated apoptosis is actively suppressed in cultured cells. J. Am. Soc. Nephrol. 7:1692.
7. Clement, M.V., and I. Stamenkovic. 1994. Fas and tumor

151 Biancone et al.
necrosis factor receptor-mediated cell death: similarities and distinctions. J. Exp. Med. 180:557–567.
8. Lagresle, C., P. Mondiere, C. Bella, P.H. Krammer, and T. Debrance. 1996. Concurrent engagement of CD40 and the antigen receptor protects naive and memory cells from APO-1/Fas-mediated apoptosis. J. Exp. Med. 180:1377–1388.
9. Alderson, M.R., R. J. Armitage, E. Maraskovsky, T.W. Tough, E. Roux, K. Schooley, F. Randsell, and D.H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178:2231–2235.
10. Ponton, A., M.-V. Clement, and I. Stamenkovic. 1996. The CD95 (APO-1/Fas) R receptor activates NF-kB independently of its cytotoxic function. J. Biol. Chem. 271:8991–8995.
11. Rensing-Ehl, A., S. Hess, H.W. Ziegler-Hellbrock, G. Riemmuller, and H. Engelmann. 1995. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J. Inflamm. 45:161–174.
12. Aggarwal, B.B., S. Singh, R. LaPushin, and K. Totpal. 1995. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett. 364:5–8.
13. Watanabe-Fukunaga, R., C.J. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.). 356:314–317.
14. Passaniti, A., R.M. Taylor, R. Pili, Y. Guo, P.V. Long, J.A. Haney, R.R. Pauly, D.S. Grant, and G.R. Martin. 1992. A simple quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519–528.
15. Montrucchio, G., E. Lupia, E. Battaglia, G. Passerini, F. Bussozino, G. Emanuelli, and G. Camussi. 1994. Tumor necrosis factor α-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J. Exp. Med. 180:377–382.
16. Gavrieli, Y., Y. Sherman, and S.A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119:493–501.
17. Nishimura, Y., A. Ishii, Y. Kobayashi, Y. Yamasaki, and S. Yonehara. 1995. Expression and function of mouse Fas antigen on immature and mature T cells. J. Immunol. 154:4395–4403.
18. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: Ipr and gld mutations. Immunol. Today. 16:39–43.
19. Beutler, B., and C. Van Hulffel. 1994. Unraveling function in the T NF ligand and receptor families. Science (Wash. D.C.). 264:667–668.
20. Hess, S., and H. Engelmann. 1996. A novel function of CD40: induction of cell death in transformed. J. Exp. Med. 183:159–167.
21. Leung, D.W., G. Cachianes, W.-J. Kuang, D.V. Goeddel, and N. Ferrara. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Wash. D.C.). 246:1306–1309.
22. Yagita, H., K.-I. Seino, N. Kayagaki, and K. Okumura. 1996. CD95 ligand in graft rejection. Nature (Lond.). 379:682.
23. Lowrance, J.H., F.X. O'Sullivan, T.E. Caver, W. Waegell, and H.D. Gresham. 1994. Spontaneous elaboration of transforming growth factor β suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J. Exp. Med. 180:1693–1703.
24. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Matoyoshi, M. Mizuki, S. Tagawa, S. Ohga et al. 1996. Fas ligand in human serum. Nat. Med. 2:317–322.